Abstract:Protein glycosylation is the co‐ and/or post‐translational modification of proteins with oligosaccharides (glycans). This process is not template based and can introduce a heterogeneous set of glycan modifications onto substrate proteins. Glycan structures preserve biomolecular information from the cell, with glycoproteins from different cell types and tissues displaying distinct patterns of glycosylation. Several decades of research have revealed that glycan structures also differ between normal physiology and disease. This suggests that the information stored in glycoproteins and glycans can be utilized for disease diagnosis and monitoring. Methods that enable sensitive and site‐specific measurement of protein glycosylation in clinical settings, such as nano‐flow liquid chromatography tandem mass spectrometry, are therefore essential. The purpose of this perspective is to discuss recent advances in mass spectrometry and the potential of these advances to facilitate the detection and monitoring of disease‐specific glycoprotein glycoforms. Glycoproteomics, the system‐wide characterization of glycoprotein identity inclusive of site‐specific characterization of carbohydrate modifications on proteins, and glycomics, the characterization of glycan structures, will be discussed in this context. Quantitative measurement of glycopeptide markers via parallel reaction monitoring is highlighted. The development of promising glycopeptide markers for autoimmune disease, liver disease, and liver cancer is discussed. Synthetic glycopeptide standards, ambient ionization mass spectrometry, and consideration of glyco‐biomarkers in two‐ and three‐dimensional space within tissue will be critical to the advancement of this field. The authors envision a future in which glycoprotein mass spectrometry workflows will be integrated into clinical settings, to aid in the rapid diagnosis and monitoring of disease.

Glycomic technology and its application in disease marker mining

Imaging of protein-specific glycosylation by glycan metabolic tagging and in situ proximity ligation.

Mass Spectrometry-Based N-glycoproteomics for Cancer Biomarker Discovery.

Sweet systems: technologies for glycomic analysis and their integration into systems biology

Recent Progress in Quantitative Glycoproteomics.

Progress of technology and methodology in quantitative glycoproteomics

GP-Marker facilitates the analysis of intact glycopeptide quantitative data at different levels

Progress of Proteomics Driven Precision Medicine-From a Glycosylation View.

Clinical glycoprotein mass spectrometry: The future of disease detection and monitoring

Biomarker Discovery via N-Glycoproteomics

Strategies for Proteome-Wide Quantification of Glycosylation Macro- and Micro-Heterogeneity

Lectin microarrays: a powerful tool for glycan-based biomarker discovery.

Applications and continued evolution of glycan imaging mass spectrometry

Current Technologies for Complex Glycoproteomics and Their Applications to Biology/Disease-Driven Glycoproteomics.

Advancements in mass spectrometry-based glycoproteomics and glycomics

Glycans, Glycosite, and Intact Glycopeptide Analysis of N-Linked Glycoproteins Using Liquid Handling Systems

Integrated Pipeline of Isotopic Labeling and Selective Enriching for Quantitative Analysis of N-Glycome by Mass Spectrometry.

Mass spectrometry-based structure-specific N- glycoproteomics and biomedical applications

Advances in Sample Preparation Strategies for MS-based Qualitative and Quantitative N-glycomics

Providing Bionic Glycome As Internal Standards by Glycan Reducing and Isotope Labeling for Reliable and Simple Quantitation of N-glycome Based on MALDI- MS.

Comparison of the methods for profiling N-glycans—hepatocellular carcinoma serum glycomics study